Lyell Immunopharma Inc (LYEL)

$16.93 -0.48 (-2.76%)
Market Cap 334.46M
Revenue (ttm) 60,000.00
Net Income (ttm) -342.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -571,650.00%
Debt to Equity Ratio 0.00
Volume 18,200
Avg Vol 43,968
Day's Range N/A - N/A
Shares Out 19.21M
Stochastic %K 42%
Beta -0.07
Analysts Hold
Price Target $11.00

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 695 0677
Address:
201 Haskins Way, South San Francisco, United States
Mdugs
Mdugs Nov. 14 at 7:50 PM
$LYEL interesting to see them acquire something. While cash is tight I think they either have bad trial results coming… or very good so they can raise more cash. Anyone still here?
1 · Reply
d_risk
d_risk Nov. 12 at 10:26 PM
$LYEL - Lyell Immunopharma Inc. Common Stock - 10Q - Updated Risk Factors LYEL’s latest 10-Q details heightened risks in manufacturing, clinical trials, supply chain, IP rights, Nasdaq compliance, capital needs, and commercialization, with new focus on acquisitions, workforce reductions, regulatory scrutiny, and expanded legal and tax exposures. #ManufacturingRisks #ClinicalTrials #Biotechnology #TaxExposure #LegalRisks #WorkforceReduction #Acquisitions #CapitalNeeds #RegulatoryCompliance #IntellectualProperty #SupplyChain 🟢 Added 🟠 Removed https://d-risk.ai/LYEL/10-Q/2025-11-12
0 · Reply
None_
None_ Nov. 12 at 3:11 AM
$LYEL https://www.fiercebiotech.com/biotech/lyell-signs-185m-deal-impressive-phase-1-stage-colorectal-cancer-car-t
0 · Reply
fantastex
fantastex Nov. 3 at 2:26 PM
$LYEL 7/12....
0 · Reply
fantastex
fantastex Oct. 31 at 12:41 PM
$LYEL so nervous, but I feel inside myself that this will skyrocket sooner or later
1 · Reply
Hopipaytrader
Hopipaytrader Oct. 22 at 5:07 PM
$LYEL anyone see the overnight -25%
0 · Reply
Hopipaytrader
Hopipaytrader Oct. 22 at 3:25 AM
$LYEL ok deep handle time?
0 · Reply
Hopipaytrader
Hopipaytrader Oct. 17 at 12:28 PM
$LYEL good morning
0 · Reply
fantastex
fantastex Oct. 17 at 11:20 AM
$LYEL the big pump is yet to come.
0 · Reply
Hopipaytrader
Hopipaytrader Oct. 16 at 12:54 AM
$LYEL beauty
1 · Reply
Latest News on LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Nov 12, 2025, 4:05 PM EST - 2 days ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Nov 10, 2025, 7:30 AM EST - 5 days ago

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:00 AM EST - 11 days ago

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Sep 3, 2025, 8:00 AM EDT - 2 months ago

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Lyell Immunopharma Announces Participation in September Investor Conferences

Sep 2, 2025, 4:05 PM EDT - 2 months ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Aug 12, 2025, 4:05 PM EDT - 3 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Jul 25, 2025, 8:00 AM EDT - 4 months ago

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Jul 22, 2025, 9:02 AM EDT - 4 months ago

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 23, 2025, 5:00 PM EDT - 5 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Jun 17, 2025, 6:30 AM EDT - 5 months ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Jun 9, 2025, 4:05 PM EDT - 5 months ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 5 months ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 13, 2025, 4:05 PM EDT - 6 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

May 1, 2025, 9:00 AM EDT - 7 months ago

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Apr 15, 2025, 9:00 AM EDT - 7 months ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 4:05 PM EDT - 8 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Feb 18, 2025, 4:05 PM EST - 9 months ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Jan 9, 2025, 9:00 AM EST - 11 months ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Dec 9, 2024, 9:00 PM EST - 1 year ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 5, 2024, 9:30 AM EST - 1 year ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 31, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 25, 2024, 9:24 AM EDT - 1 year ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Sep 24, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16, 2024, 6:25 PM EDT - 1 year ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 28, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Lyell Immunopharma Announces Participation in March Investor Conferences

Feb 26, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 10, 2023, 2:23 PM EST - 2 years ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 9, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 26, 2023, 9:29 AM EDT - 2 years ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

May 4, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

May 2, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Feb 28, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Dec 15, 2022, 7:00 AM EST - 3 years ago

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Dec 1, 2022, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Nov 10, 2022, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Mdugs
Mdugs Nov. 14 at 7:50 PM
$LYEL interesting to see them acquire something. While cash is tight I think they either have bad trial results coming… or very good so they can raise more cash. Anyone still here?
1 · Reply
d_risk
d_risk Nov. 12 at 10:26 PM
$LYEL - Lyell Immunopharma Inc. Common Stock - 10Q - Updated Risk Factors LYEL’s latest 10-Q details heightened risks in manufacturing, clinical trials, supply chain, IP rights, Nasdaq compliance, capital needs, and commercialization, with new focus on acquisitions, workforce reductions, regulatory scrutiny, and expanded legal and tax exposures. #ManufacturingRisks #ClinicalTrials #Biotechnology #TaxExposure #LegalRisks #WorkforceReduction #Acquisitions #CapitalNeeds #RegulatoryCompliance #IntellectualProperty #SupplyChain 🟢 Added 🟠 Removed https://d-risk.ai/LYEL/10-Q/2025-11-12
0 · Reply
None_
None_ Nov. 12 at 3:11 AM
$LYEL https://www.fiercebiotech.com/biotech/lyell-signs-185m-deal-impressive-phase-1-stage-colorectal-cancer-car-t
0 · Reply
fantastex
fantastex Nov. 3 at 2:26 PM
$LYEL 7/12....
0 · Reply
fantastex
fantastex Oct. 31 at 12:41 PM
$LYEL so nervous, but I feel inside myself that this will skyrocket sooner or later
1 · Reply
Hopipaytrader
Hopipaytrader Oct. 22 at 5:07 PM
$LYEL anyone see the overnight -25%
0 · Reply
Hopipaytrader
Hopipaytrader Oct. 22 at 3:25 AM
$LYEL ok deep handle time?
0 · Reply
Hopipaytrader
Hopipaytrader Oct. 17 at 12:28 PM
$LYEL good morning
0 · Reply
fantastex
fantastex Oct. 17 at 11:20 AM
$LYEL the big pump is yet to come.
0 · Reply
Hopipaytrader
Hopipaytrader Oct. 16 at 12:54 AM
$LYEL beauty
1 · Reply
DreamCreator
DreamCreator Oct. 9 at 10:43 PM
Keep a close watch on CMCT! $INAB $OGEN $AGMH $LYEL 1
0 · Reply
fantastex
fantastex Oct. 6 at 8:03 PM
$LYEL if $SPRB went up 1600% this Company with breakthrough ph2/ph3 phase should go at 200$ overnight! Lol Such
0 · Reply
ObscureCandle
ObscureCandle Oct. 5 at 11:00 AM
$LYEL Biotech speculation. Pre-revenue stage. Chart shows high risk/reward. No pattern recognition.
1 · Reply
DreamCreator
DreamCreator Oct. 3 at 12:44 AM
$LYEL $EKSO $BINI $ARBB -
1 · Reply
Hopipaytrader
Hopipaytrader Oct. 1 at 1:41 PM
$LYEL shinkansen is leaving the station
1 · Reply
ASKING7
ASKING7 Sep. 30 at 8:20 PM
$LYEL nice move recently
0 · Reply
fantastex
fantastex Sep. 30 at 6:56 PM
$LYEL many sleepers on this. +200/300% move anytime
0 · Reply
Coach757
Coach757 Sep. 30 at 12:33 PM
$LYEL Is it true Bill Gates took a 5% position in this?
1 · Reply
Hopipaytrader
Hopipaytrader Sep. 25 at 12:40 AM
$LYEL terrible chart ;)
1 · Reply
fantastex
fantastex Sep. 24 at 2:31 PM
$LYEL 15+ next week.
0 · Reply
Malgo
Malgo Sep. 23 at 12:12 AM
$LYEL Monthly chart say 33.
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 9:22 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $CATX $FTEK $ANIX $LIVE $LYEL www
0 · Reply